title: Phase I trial of dasatinib and ixabepilone in patients with solid tumors.
abstract: OBJECTIVE
  Dasatinib is an oral tyrosine kinase inhibitor (TKI) of BCR-ABL and SRC family and ixabepilone is an epothilone B analog. Synergistic activity has been reported when combining dasatinib with chemotherapy. This study was conducted to determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) for this combination.
  
  
  METHODS
  Patients with metastatic solid tumors who progressed on standard therapy received dasatinib orally daily and ixabepilone IV every 3 weeks at escalating doses using 3 + 3 design. An expansion cohort was studied after reaching the MTD. Pharmacokinetic studies were performed.
  
  
  RESULTS
  Nineteen patients were enrolled. No DLTs were observed at dose level (DL) 1 (dasatinib 100 mg and ixabepilone 30 mg/m(2)). At DL 2 (dasatinib 100 mg and ixabepilone 40 mg/m(2)), one patient had multiple DLTs. At DL 3 (dasatinib 150 mg and ixabepilone 40 mg/m(2)), the first patient developed grade 3 AE during cycle 2, the second patient had a DLT and a grade 3 AE during cycle 2. The accrual to DL 3 was halted without reaching the maximally administered dose (MAD) and MTDs were determined to be dasatinib 100 mg and ixabepilone 40 mg/m(2) (DL 2). One patient had a partial response and 12 patients stable disease as their best response. Fourteen patients came off study due to toxicities.
  
  
  CONCLUSIONS
  The combination of dasatinib and ixabepilone showed modest clinical activity with doses 100 mg orally daily and 40 mg/m(2) IV every 3 weeks, respectively. Treatment related toxicities were seen frequently.
authors.affiliation: Washington Cancer Institute/ Medstar Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA. Pia.M.Herbolsheimer@Medstar.net
authors.forename: P
authors.initials: P
authors.lastname: Herbolsheimer
authors.forename: R
authors.initials: R
authors.lastname: Kapoor
authors.forename: K L
authors.initials: KL
authors.lastname: Smith
authors.forename: D
authors.initials: D
authors.lastname: Perry
authors.forename: N
authors.initials: N
authors.lastname: Verma
authors.forename: I
authors.initials: I
authors.lastname: Veytsman
authors.forename: J
authors.initials: J
authors.lastname: Jelinek
authors.forename: S M
authors.initials: SM
authors.lastname: Swain
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000069439:Dasatinib; D034261:Epothilones / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D013844:Thiazoles / Q000008:administration & dosage; D050257:Tubulin Modulators / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D034261:Epothilones; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D050257:Tubulin Modulators; C430592:ixabepilone; D000069439:Dasatinib